Study demonstrates that six months of high-impact unilateral exercise significantly improves femoral neck bone density in postmenopausal women without negatively affecting knee osteoarthritis progression.
Merck’s Keytruda receives approval greenlight from EU CHMP –
Keytruda is an anti-programmed death receptor-1 therapy that helps enhance the capability of the body’s immune system. Credit: Merck & Co. The European Medicines Agency’s
October 13, 2023